Portfolio Growth Civilization Ventures manages a sizable portfolio worth 9.7B across 64 companies with multiple exits, indicating an active deal flow and potential for co-investment, follow-on funding opportunities, and strategic partnerships with portfolio founders.

Healthcare Focus The firm concentrates on biology and healthcare, including biotech, synthetic biology, and age-related therapeutics, presenting if your solution targets these areas there is alignment for collaboration, investment syndication, or advisory roles.

Strategic Co-Investors Recent investments feature prominent co-leads and notable VCs like Sanofi Ventures, Lux Capital, Y Combinator, and Initialized Capital, signaling openness to syndication and the potential to engage with other backers via joint opportunities.

Recent Fundraising Activity Active in 2024–2025 with multiple Series A and seed rounds across Curve Biosciences, Trial Library, 10x Science, and Integrated Biosciences, suggesting ongoing appetite for early to growth-stage biotech deals and potential warm introductions to portfolio companies.

Regional and Tech Footprint Based in San Francisco with a tech-forward stack and substantial clinical and translational biology exposure, offering opportunities for collaboration in San Francisco Bay Area biotech hubs and leveraging adjacent technology providers to accelerate portfolio companies.